Active Watch List: Receptos (NASDAQ:RCPT), Cytokinetics, Incorporated (NASDAQ:CYTK), EMC Corporation (NYSE:EMC), Oncothyreon Inc (NASDAQ:ONTY), Albany Molecular Research Inc. (NASDAQ:AMRI)

On Friday shares of Receptos, Inc. (NASDAQ:RCPT) closed at $153.86. On May 7, Receptos, Inc. (NASDAQ:RCPT), announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Bank of America Merrill Lynch 2015 Healthcare Conference at the Encore Hotel in Las Vegas, NV. The presentation is scheduled for Wednesday, May 13th at 3:00pm Pacific time.

Cytokinetics, Incorporated (NASDAQ:CYTK) in last trading activity increased 6.51% to close at $6.38. Company weekly performance is 12.92% while its quarterly performance stands at 0.16%. Cytokinetics, Incorporated (NASDAQ:CYTK) is -25.90% away from its 52 week high. Cytokinetics Inc. (CYTK) on Thursday reported a loss of $8.9 million in its first quarter.

On last trading day EMC Corporation (NYSE:EMC) increased 2.86% to close at $26.93. Its volatility for the week is 1.85% while volatility for the month is 1.70%. EMC’s sales growth for past 5 years was 11.70% and its EPS growth for past 5 years was 20.00%. EMC Corporation (NYSE:EMC) monthly performance is 3.78%. On May 04, EMC Corporation (NYSE:EMC) announced new updates to the EMC® VMAX3™ platform, the industry’s leading data service platform, fundamentally changing what has been possible with enterprise storage by delivering new levels of automation, modernization and consolidation to customers. EMC is extending enterprise data services to multiple platforms with the launch of FAST.X™, automating storage tiering across the data center.

Oncothyreon Inc (NASDAQ:ONTY) has 0.10% insider ownership while its institutional ownership stands at 55.90%. In last trading activity company’s stock closed at $1.75. Oncothyreon Inc. (NASDAQ:ONTY) announced that it will conduct a conference call on Monday, May 11, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its first quarter 2015 financial results

On last trading day Albany Molecular Research Inc. (NASDAQ:AMRI) fell -1.54% to close at $19.20. Its volatility for the week is 4.69% while volatility for the month is 3.84%. AMRI’s sales growth for past 5 years was 7.10% and its EPS growth for past 5 years was 28.60%. Albany Molecular Research Inc. (NASDAQ:AMRI) monthly performance is 3.28%. On May 5, AMRI (NASDAQ:AMRI) reported financial and operating results for the first quarter ended March 31, 2015. Total revenue for the first quarter of 2015 was $81.8 million, an increase of 38% compared to total revenue of $59.3 million reported in the first quarter of 2014.

Leave a Reply

Your email address will not be published. Required fields are marked *